Dabrafenib (GSK2118436A) | BRAF Inhibitor

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	1195765-45-7
Formula :	C₂₃H₂₀F₃N₅O₂S₂
M.W :	519.56
SMILES Code :	O=S(C1=C(F)C=CC=C1F)(NC2=CC=CC(C3=C(C4=NC(N)=NC=C4)SC(C(C)(C)C)=N3)=C2F)=O
Synonyms :	GSK2118436A; GSK2118436
MDL No. :	MFCD17215684
InChI Key :	BFSMGDJOXZAERB-UHFFFAOYSA-N
Pubchem ID :	44462760

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Primary murine melanoma cells from TBP mice	500 nM	10 days	To evaluate the inhibitory effect of Dabrafenib on melanoma spheroids, results showed that Dabrafenib significantly reduced the volume of spheroids.	PMC10478295
BGC823 cells	10μM	48 h	Dabrafenib significantly reduced the number of invaded BGC823 cells, indicating inhibition of cell invasion	PMC8116207
MKN74 cells	10μM	72 h	Dabrafenib significantly reduced the number of invaded MKN74 cells, indicating inhibition of cell invasion	PMC8116207
BGC823 cells	10μM	24 h	Dabrafenib significantly reduced the number of migrated BGC823 cells, indicating inhibition of cell migration	PMC8116207
MKN74 cells	10μM	48 h	Dabrafenib significantly reduced the number of migrated MKN74 cells, indicating inhibition of cell migration	PMC8116207
BGC823 cells	10μM	72 h	Dabrafenib significantly delayed wound closure in BGC823 cells, indicating inhibition of cell migration	PMC8116207
MKN74 cells	10μM	72 h	Dabrafenib significantly delayed wound closure in MKN74 cells, indicating inhibition of cell migration	PMC8116207
BGC823 cells	10μM	48 h	Dabrafenib significantly inhibited invasion ability of BGC823 cells	PMC8116207
MKN74 cells	10μM	72 h	Dabrafenib significantly inhibited invasion ability of MKN74 cells	PMC8116207
BGC823 cells	10μM	24 h	Dabrafenib significantly inhibited migration ability of BGC823 cells	PMC8116207
MKN74 cells	10μM	48 h	Dabrafenib significantly inhibited migration ability of MKN74 cells	PMC8116207
BGC823 cells	10μM	72 h	Dabrafenib significantly inhibited wound healing and migration ability of BGC823 cells	PMC8116207
MKN74 cells	10μM	72 h	Dabrafenib significantly inhibited wound healing and migration ability of MKN74 cells	PMC8116207
Inner ear cell line	30 nM		Dabrafenib at a concentration of 30 nM protected neonatal mouse cochlear outer hair cells from cisplatin-induced cell death with a therapeutic index greater than 2000.	PMC10807719
A375 melanoma cells	1 μM	9 days or more	To investigate the effect of Dabrafenib on A375 melanoma cells, results showed that these cells developed resistance to Dabrafenib treatment, but the resistance was reversible.	PMC5933935
MM200 cells	100 nM	24 h	To assess the contribution of PI3K/AKT signaling in BRAF/MEK inhibitor resistance, results showed that PI3K/AKT activation promoted cell survival but did not restore MAPK signaling.	PMC6148266
SKMel28 cells	100 nM	24 h	To assess the contribution of PI3K/AKT signaling in BRAF/MEK inhibitor resistance, results showed that PI3K/AKT activation promoted cell survival but did not restore MAPK signaling.	PMC6148266
WM164 cells	160 nM	72 h	To assess the heterogeneity of MITF expression during BRAF inhibitor treatment, the results showed that MITF expression remained heterogeneous during treatment.	PMC5538298

Mice	TBP mouse melanoma model	Oral	30 mg/kg	Once daily for 5 weeks	To evaluate the therapeutic effect of Dabrafenib on melanoma, results showed that Dabrafenib significantly reduced tumor volume, but eventually all tumors developed resistance.	PMC10478295
Nude mice	Peritoneal metastasis model	Intraperitoneal injection	5 mg/kg	Every 3 days for 28 days	Dabrafenib significantly reduced the number of peritoneal metastases, indicating inhibition of peritoneal metastasis	PMC8116207
Nude mice	Peritoneal metastasis model	Intraperitoneal injection	5 mg/kg	Every 3 days for 28 days	Dabrafenib significantly inhibited peritoneal metastasis of MKN74 cells in nude mice	PMC8116207
Mice	Multidose cisplatin mouse model	Oral	3 mg/kg	Twice daily for 42 days	Dabrafenib at a dose of 3 mg/kg BW, administered twice daily, significantly protected mice from cisplatin-induced hearing loss, and the protective effect persisted for 4 months after the completion of treatment.	PMC10807719
Nude mice	A375 melanoma xenograft model	Oral gavage	100 mg/kg	Twice daily, until tumour relapse	To investigate the effect of Dabrafenib on the A375 melanoma xenograft model, results showed that GPX4 KO tumours did not relapse after Dabrafenib treatment, while GPX4 WT tumours relapsed.	PMC5933935
Mice	A375 tumor model	Oral	25 mg/kg	Once daily for 20 days	To evaluate the effect of Dabrafenib combined with EDNR inhibitors on tumor growth, the results showed that combination therapy significantly inhibited tumor growth and reduced the number of AXL-high expressing cells.	PMC5538298

{[proInfo.proName]}

CAS No.: 1195765-45-7

{[proInfo.proName]}

CAS No.: 1195765-45-7

Alternative Products

Product Details of Dabrafenib

Safety of Dabrafenib

Related Pathways of Dabrafenib

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT01682213	Melanoma	PHASE2	COMPLETED	2025-05-19	Memorial Sloan Kettering Cance... More >>r Center, New York, New York, 10065, United States Less <<
NCT01262963	Cancer	PHASE1	COMPLETED	2011-04-08	GSK Investigational Site, Taco... More >>ma, Washington, 98418, United States Less <<
NCT01534897	Papillary Thyroid Carcinoma		COMPLETED	2025-03-14	Massachusetts General Hospital... More >>, Boston, Massachusetts, 02215, United States Less <<
NCT06264778	Ameloblastoma	PHASE3	NOT_YET_RECRUITING	2025-12-31	-
NCT01582997	Cancer	PHASE1	COMPLETED	2015-04-16	GSK Investigational Site, Shiz... More >>uoka, 411-8777, Japan\|GSK Investigational Site, Tokyo, 104-0045, Japan Less <<
NCT01266967	Melanoma and Brain Metastases	PHASE2	COMPLETED	2025-11-12	GSK Investigational Site, Los ... More >>Angeles, California, 90095, United States\|GSK Investigational Site, San Francisco, California, 94115, United States\|GSK Investigational Site, San Francisco, California, 94143, United States\|GSK Investigational Site, Ann Arbor, Michigan, 48019, United States\|GSK Investigational Site, New York, New York, 10065, United States\|GSK Investigational Site, Pittsburgh, Pennsylvania, 15232, United States\|GSK Investigational Site, Nashville, Tennessee, 37232, United States\|GSK Investigational Site, Houston, Texas, 77030, United States\|GSK Investigational Site, Seattle, Washington, 98109, United States\|GSK Investigational Site, Waratah, New South Wales, 2300, Australia\|GSK Investigational Site, Westmead, New South Wales, 2145, Australia\|GSK Investigational Site, Nedlands, Western Australia, 6009, Australia\|GSK Investigational Site, Edmonton, Alberta, T6G 1Z2, Canada\|GSK Investigational Site, Toronto, Ontario, M5G 2M9, Canada\|GSK Investigational Site, Montreal, Quebec, H3T 1E2, Canada\|GSK Investigational Site, Boulogne-Billancourt, 92100, France\|GSK Investigational Site, Lille, 59037, France\|GSK Investigational Site, Marseille Cedex 5, 13385, France\|GSK Investigational Site, Villejuif, 94805, France\|GSK Investigational Site, Essen, Nordrhein-Westfalen, 45122, Germany\|GSK Investigational Site, Kiel, Schleswig-Holstein, 24105, Germany\|GSK Investigational Site, Berlin, 10117, Germany\|GSK Investigational Site, Napoli, Campania, 80131, Italy\|GSK Investigational Site, Padova, Veneto, 35128, Italy Less <<
NCT01153763	Melanoma	PHASE2	COMPLETED	2016-06-01	GSK Investigational Site, Los ... More >>Angeles, California, 90025, United States\|GSK Investigational Site, Los Angeles, California, 90095, United States\|GSK Investigational Site, San Francisco, California, 94115, United States\|GSK Investigational Site, Philadelphia, Pennsylvania, 19104, United States\|GSK Investigational Site, Nashville, Tennessee, 37232, United States\|GSK Investigational Site, Houston, Texas, 77030-4009, United States\|GSK Investigational Site, Newcastle, New South Wales, 2300, Australia\|GSK Investigational Site, Westmead, New South Wales, 2145, Australia\|GSK Investigational Site, Nedlands, Western Australia, 6009, Australia\|GSK Investigational Site, Bordeaux, 33075, France\|GSK Investigational Site, Boulogne-Billancourt, 92100, France\|GSK Investigational Site, Lille, 59037, France\|GSK Investigational Site, Marseille Cedex 5, 13385, France\|GSK Investigational Site, Montpellier, 34295, France\|GSK Investigational Site, Paris Cedex 10, 75475, France\|GSK Investigational Site, Villejuif, 94805, France\|GSK Investigational Site, Essen, Nordrhein-Westfalen, 45122, Germany\|GSK Investigational Site, Kiel, Schleswig-Holstein, 24105, Germany\|GSK Investigational Site, Luebeck, Schleswig-Holstein, 23538, Germany\|GSK Investigational Site, Berlin, 10117, Germany\|GSK Investigational Site, Napoli, Campania, 80131, Italy\|GSK Investigational Site, Genova, Liguria, 16132, Italy\|GSK Investigational Site, Padova, Veneto, 35128, Italy Less <<
NCT01677741	Neoplasms, Brain	PHASE1\|PHASE2	COMPLETED	2020-12-04	Novartis Investigative Site, P... More >>hoenix, Arizona, 85016-7710, United States\|Novartis Investigative Site, Orange, California, 92868, United States\|Novartis Investigative Site, Baltimore, Maryland, 21287, United States\|Novartis Investigative Site, Boston, Massachusetts, 02215, United States\|Novartis Investigative Site, New York, New York, 10065, United States\|Novartis Investigative Site, Cincinnati, Ohio, 45229, United States\|Novartis Investigative Site, Memphis, Tennessee, 38105-3678, United States\|Novartis Investigative Site, Seattle, Washington, 98105, United States\|Novartis Investigative Site, Parkville, Victoria, 3052, Australia\|Novartis Investigative Site, Toronto, Ontario, M5G 1X8, Canada\|Novartis Investigative Site, Copenhagen, DK-2100, Denmark\|Novartis Investigative Site, Marseille Cedex 5, 13385, France\|Novartis Investigative Site, Paris cedex 05, 75248, France\|Novartis Investigative Site, Paris cedex 12, 75571, France\|Novartis Investigative Site, Toulouse cedex 9, 31059, France\|Novartis Investigative Site, Villejuif Cedex, 94805, France\|Novartis Investigative Site, Heidelberg, Baden-Wuerttemberg, 69120, Germany\|Novartis Investigative Site, Regensburg, Bayern, 93053, Germany\|Novartis Investigative Site, Berlin, 13353, Germany\|Novartis Investigative Site, Jerusalem, 91120, Israel\|Novartis Investigative Site, Ramat-Gan, 52621, Israel\|Novartis Investigative Site, Milan, 20133, Italy\|Novartis Investigative Site, Esplugues De Llobregat. Barcelona, 08950, Spain\|Novartis Investigative Site, Madrid, 28009, Spain\|Novartis Investigative Site, Sutton, Surrey, SM2 5PT, United Kingdom\|Novartis Investigative Site, London, WC1N 3JH, United Kingdom Less <<
NCT01340833	Cancer	PHASE1	COMPLETED	2011-09-12	GSK Investigational Site, Taco... More >>ma, Washington, 98418, United States Less <<

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed